CN1997354A - 有机化合物的盖仑制剂 - Google Patents
有机化合物的盖仑制剂 Download PDFInfo
- Publication number
- CN1997354A CN1997354A CNA2005800062331A CN200580006233A CN1997354A CN 1997354 A CN1997354 A CN 1997354A CN A2005800062331 A CNA2005800062331 A CN A2005800062331A CN 200580006233 A CN200580006233 A CN 200580006233A CN 1997354 A CN1997354 A CN 1997354A
- Authority
- CN
- China
- Prior art keywords
- dosage form
- solid per
- per
- heart failure
- aliskiren
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Description
滚筒压片片剂 | 剂型1 | 剂型2 | 剂型3 | |
组分 | ||||
半延胡索酸阿利吉仑微晶纤维素聚乙烯吡咯烷酮K30CrospovidoneAerosil 200硬脂酸镁总重量 | 165.750220.650-84.0004.8004.8004800.000 | 165.75084.750-45.0001.5003.000300.000 | 165.75072.25012.00044.0001.5004.500300.000 | 165.750107.25012.00048.2001.8005.000340.000 |
滚筒压片片剂 | 剂型1 | 剂型2 | 剂型3 | |
组分 | ||||
半延胡索酸阿利吉仑微晶纤维素聚乙烯吡咯烷酮K30CrospovidoneAerosil 200硬脂酸镁总% | 34.5345.97-17.511100.00 | 55.2528.25-150.51100.00 | 55.2524.08414.670.51.5100.00 | 48.7531.5453.5314.1750.531.47100.00 |
滚筒压片片剂 | 剂型1 | 剂型2 | 剂型3 |
组分 | |||||
内相外相 | 半延胡索酸阿利吉仑微晶纤维素聚乙烯吡咯烷酮K30CrospovidoneAerosil 200硬脂酸镁Crospovidone微晶纤维素Aerosil 200硬脂酸镁总重量 | 165.75220.65-36.00-2.4048.00-4.802.40480.00 | 165.7584.75----45.00-1.503.00300.00 | 165.7572.2512.00---44.00-1.504.50300.00 | 165.7590.2512.0014.20--34.0017.001.805.00340.00 |
滚筒压片片剂 | 剂型1 | 剂型2 | 剂型3 | ||
组分 | |||||
内相外相 | 半延胡索酸阿利吉仑微晶纤维素聚乙烯吡咯烷酮K30CrospovidoneAerosil 200硬脂酸镁Crospovidone微晶纤维素Aerosil 200硬脂酸镁总% | 34.5345.97-7.5-0.510-10.5100.00 | 55.2528.25----15-0.51100.00 | 55.2524.084---14.67-0.51.5100.00 | 48.7526.5453.5304.175--1050.531.47100.00 |
剂型3/强度组分 | 75mg(游离碱) | 150mg(游离碱) | 300mg(游离碱) |
半延胡索酸阿利吉仑微晶纤维素聚乙烯吡咯烷酮K30CrospovidoneAerosil 200硬脂酸镁总片剂重量Opadry premix whiteOpadry premix redOpadry premix black薄膜衣片剂总重量 | 82.87553.6256.00024.1000.9002.500170.0009.9460.0240.030180.000 | 165.750107.25012.00048.2001.8005.000340.00016.7110.2380.051357.000 | 331.500214.50024.00096.4003.60010.000680.00023.96161.83820.2002706.000 |
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55387804P | 2004-03-17 | 2004-03-17 | |
US60/553,878 | 2004-03-17 | ||
PCT/EP2005/002798 WO2005089729A2 (en) | 2004-03-17 | 2005-03-16 | Galenic formulations of organic compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013103391479A Division CN103462913A (zh) | 2004-03-17 | 2005-03-16 | 有机化合物的盖仑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1997354A true CN1997354A (zh) | 2007-07-11 |
CN1997354B CN1997354B (zh) | 2013-09-11 |
Family
ID=34994415
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800062331A Active CN1997354B (zh) | 2004-03-17 | 2005-03-16 | 有机化合物的盖仑制剂 |
CN2013103391479A Pending CN103462913A (zh) | 2004-03-17 | 2005-03-16 | 有机化合物的盖仑制剂 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013103391479A Pending CN103462913A (zh) | 2004-03-17 | 2005-03-16 | 有机化合物的盖仑制剂 |
Country Status (24)
Country | Link |
---|---|
US (3) | US8617595B2 (zh) |
EP (2) | EP1729736A2 (zh) |
JP (2) | JP2007529456A (zh) |
KR (2) | KR101274855B1 (zh) |
CN (2) | CN1997354B (zh) |
AR (1) | AR048431A1 (zh) |
AU (2) | AU2005224010B2 (zh) |
BR (1) | BRPI0508833A (zh) |
CA (1) | CA2554633C (zh) |
EC (1) | ECSP066807A (zh) |
ES (1) | ES2747941T3 (zh) |
IL (1) | IL177424A0 (zh) |
MA (1) | MA28490B1 (zh) |
MX (1) | MX347617B (zh) |
MY (2) | MY148773A (zh) |
NO (1) | NO343217B1 (zh) |
NZ (1) | NZ548823A (zh) |
PE (3) | PE20110121A1 (zh) |
RU (3) | RU2384328C2 (zh) |
SG (1) | SG153830A1 (zh) |
TN (1) | TNSN06294A1 (zh) |
TW (1) | TWI406656B (zh) |
WO (1) | WO2005089729A2 (zh) |
ZA (1) | ZA200606220B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102143939A (zh) * | 2008-06-06 | 2011-08-03 | 特瓦制药工业有限公司 | 阿利吉仑游离碱的固体形式 |
CN102361633A (zh) * | 2009-03-20 | 2012-02-22 | 诺瓦提斯公司 | 包含阿利吉仑的药物组合物 |
CN103099793A (zh) * | 2013-02-06 | 2013-05-15 | 中国人民解放军第二军医大学 | 片剂及其制备方法 |
CN103536576A (zh) * | 2013-10-15 | 2014-01-29 | 海南卫康制药(潜山)有限公司 | 阿利吉仑组合物胶囊 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4704755B2 (ja) * | 2002-11-05 | 2011-06-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
US20070191487A1 (en) * | 2004-03-17 | 2007-08-16 | Rigassi-Dietrich Petra G | Galenic formulations of organic compounds |
TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
GB0605688D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
EP2004167A1 (en) * | 2006-04-03 | 2008-12-24 | Novartis AG | Renin inhibitors for the treatment of hypertension |
GB0612540D0 (en) | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
WO2008061622A1 (en) * | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
US20100130616A1 (en) * | 2006-11-09 | 2010-05-27 | Novartis Ag | Salt of aliskiren with orotic acid |
JP2010518147A (ja) * | 2007-02-16 | 2010-05-27 | ノバルティス アーゲー | 有機化合物の使用 |
EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
US20090082458A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched aliskiren |
MX2010003441A (es) * | 2007-09-28 | 2010-04-21 | Novartis Ag | Formulaciones galenicas de alisquireno y valsartan. |
JP5378384B2 (ja) * | 2007-09-28 | 2013-12-25 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
JP2010540548A (ja) * | 2007-09-28 | 2010-12-24 | ノバルティス アーゲー | アリスキレンとバルサルタンの医薬組み合わせ剤 |
US20120029083A1 (en) | 2007-11-13 | 2012-02-02 | Teva Pharmaceutical Industries, Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
EP2062874B1 (en) | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
JP2010031006A (ja) * | 2008-07-17 | 2010-02-12 | Novartis Ag | 有機化合物の使用 |
JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
US9026212B2 (en) | 2008-09-23 | 2015-05-05 | Incube Labs, Llc | Energy harvesting mechanism for medical devices |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
EP2189442B1 (en) | 2008-11-20 | 2014-10-01 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process and intermediates for the preparation of aliskiren |
RU2535090C2 (ru) | 2009-01-28 | 2014-12-10 | Новартис Аг | Галеновы препараты органических соединений |
EP2393489B1 (en) | 2009-02-05 | 2014-10-08 | Krka, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
EP2216020A1 (en) | 2009-02-05 | 2010-08-11 | KRKA, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
EP2340820A1 (en) | 2009-12-16 | 2011-07-06 | KRKA, tovarna zdravil, d.d., Novo mesto | Moisture-activated granulation process |
US20120009257A1 (en) | 2009-03-20 | 2012-01-12 | Indrajit Ghosh | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren |
JP2010280601A (ja) * | 2009-06-04 | 2010-12-16 | Suntory Holdings Ltd | キシロオリゴ糖高含有錠剤 |
WO2011028919A2 (en) | 2009-09-03 | 2011-03-10 | Teva Pharmaceutical Industries Ltd. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
EP2382967A1 (de) | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
US20110268797A1 (en) | 2010-04-30 | 2011-11-03 | Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi | Multicoated aliskiren formulations |
US20130129791A1 (en) * | 2010-05-04 | 2013-05-23 | Mahmut Bilgic | Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof |
KR102237799B1 (ko) | 2012-11-14 | 2021-04-08 | 더블유.알. 그레이스 앤드 캄파니-콘. | 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물 |
RU2545833C1 (ru) * | 2013-12-03 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) | Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3039922A (en) * | 1959-08-17 | 1962-06-19 | Carter Prod Inc | Method of administering tablets having decongestant and anti-histaminic activity |
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
ES2310164T3 (es) * | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | Dispositivo de liberacion controlada por la matriz. |
US6264983B1 (en) * | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
WO2002015935A1 (fr) | 2000-08-25 | 2002-02-28 | Takeda Chemical Industries, Ltd. | Agents de reduction du fibrinogene |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
EP1250921A1 (en) * | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
JP2003015880A (ja) * | 2001-06-29 | 2003-01-17 | Toshiba Corp | 携帯情報端末およびアドインプログラム起動方法 |
EP1448190A2 (en) | 2001-10-18 | 2004-08-25 | Novartis AG | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
US20030114389A1 (en) * | 2001-11-13 | 2003-06-19 | Webb Randy Lee | Combination of organic compounds |
RU2316318C2 (ru) * | 2002-05-17 | 2008-02-10 | Новартис Аг | Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик |
JP4519640B2 (ja) * | 2002-06-28 | 2010-08-04 | シュペーデル・ファルマ・アーゲー | 非ペプチドレニン阻害薬及び界面活性剤を含有する医薬製剤 |
US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
-
2005
- 2005-03-15 PE PE2010000272A patent/PE20110121A1/es not_active Application Discontinuation
- 2005-03-15 AR ARP050100999A patent/AR048431A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2014001265A patent/PE20142101A1/es not_active Application Discontinuation
- 2005-03-15 PE PE2005000288A patent/PE20060075A1/es not_active Application Discontinuation
- 2005-03-15 MY MYPI20090494A patent/MY148773A/en unknown
- 2005-03-15 MY MYPI20051084A patent/MY144477A/en unknown
- 2005-03-16 RU RU2006136090/15A patent/RU2384328C2/ru not_active IP Right Cessation
- 2005-03-16 ES ES10177494T patent/ES2747941T3/es active Active
- 2005-03-16 TW TW094108055A patent/TWI406656B/zh active
- 2005-03-16 CA CA2554633A patent/CA2554633C/en not_active Expired - Fee Related
- 2005-03-16 CN CN2005800062331A patent/CN1997354B/zh active Active
- 2005-03-16 CN CN2013103391479A patent/CN103462913A/zh active Pending
- 2005-03-16 AU AU2005224010A patent/AU2005224010B2/en not_active Ceased
- 2005-03-16 EP EP05716117A patent/EP1729736A2/en not_active Ceased
- 2005-03-16 BR BRPI0508833-0A patent/BRPI0508833A/pt not_active Application Discontinuation
- 2005-03-16 NZ NZ548823A patent/NZ548823A/en not_active IP Right Cessation
- 2005-03-16 SG SG200904140-1A patent/SG153830A1/en unknown
- 2005-03-16 US US10/590,398 patent/US8617595B2/en active Active
- 2005-03-16 MX MX2012004612A patent/MX347617B/es unknown
- 2005-03-16 WO PCT/EP2005/002798 patent/WO2005089729A2/en active Application Filing
- 2005-03-16 EP EP10177494.1A patent/EP2283826B1/en active Active
- 2005-03-16 KR KR1020067018968A patent/KR101274855B1/ko active IP Right Grant
- 2005-03-16 KR KR1020137005111A patent/KR101353736B1/ko active IP Right Grant
- 2005-03-16 JP JP2007503280A patent/JP2007529456A/ja not_active Withdrawn
- 2005-04-29 US US11/119,273 patent/US7683054B2/en not_active Expired - Fee Related
- 2005-06-15 US US11/153,728 patent/US8007824B2/en active Active
-
2006
- 2006-07-27 ZA ZA2006/06220A patent/ZA200606220B/en unknown
- 2006-08-10 IL IL177424A patent/IL177424A0/en not_active IP Right Cessation
- 2006-08-30 EC EC2006006807A patent/ECSP066807A/es unknown
- 2006-09-15 TN TNP2006000294A patent/TNSN06294A1/en unknown
- 2006-09-27 MA MA29347A patent/MA28490B1/fr unknown
- 2006-10-16 NO NO20064670A patent/NO343217B1/no not_active IP Right Cessation
-
2009
- 2009-05-26 AU AU2009202069A patent/AU2009202069B2/en not_active Ceased
- 2009-10-20 RU RU2009138446/15A patent/RU2438661C2/ru not_active IP Right Cessation
-
2011
- 2011-08-25 RU RU2011135405/15A patent/RU2480210C1/ru not_active IP Right Cessation
-
2012
- 2012-06-06 JP JP2012129230A patent/JP5925607B2/ja active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102143939A (zh) * | 2008-06-06 | 2011-08-03 | 特瓦制药工业有限公司 | 阿利吉仑游离碱的固体形式 |
CN102361633A (zh) * | 2009-03-20 | 2012-02-22 | 诺瓦提斯公司 | 包含阿利吉仑的药物组合物 |
CN103099793A (zh) * | 2013-02-06 | 2013-05-15 | 中国人民解放军第二军医大学 | 片剂及其制备方法 |
CN103099793B (zh) * | 2013-02-06 | 2015-07-15 | 中国人民解放军第二军医大学 | 片剂及其制备方法 |
CN103536576A (zh) * | 2013-10-15 | 2014-01-29 | 海南卫康制药(潜山)有限公司 | 阿利吉仑组合物胶囊 |
CN103536576B (zh) * | 2013-10-15 | 2015-07-01 | 海南卫康制药(潜山)有限公司 | 阿利吉仑组合物胶囊 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1997354B (zh) | 有机化合物的盖仑制剂 | |
RU2491058C2 (ru) | Галеновый состав алискирена и гидрохлортиазида | |
CN101808630A (zh) | 阿利吉仑的盖仑制剂 | |
MXPA06010482A (en) | Galenic formulations of organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170511 Address after: Dublin, Ireland Patentee after: Norton pharmaceuticals Address before: Basel Patentee before: Novartis Ag |